• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ASPARAGINASE Drug Record

  • Summary
  • Interactions
  • Claims
  • ASPARAGINASE chembl:CHEMBL2108989 ApprovedAntineoplastic

    Alternate Names:

    ELSPAR
    ASPARAGINASE
    NSC-109229
    L-ASPARAGINASE
    CRASNITIN
    COLASPASE

    Drug Info:

    (1 More Sources)

    Publications:

    Alachkar H et al., 2017, Expression and polymorphism (rs4880) of mitochondrial superoxide dismutase (SOD2) and asparaginase induced hepatotoxicity in adult patients with acute lymphoblastic leukemia., Pharmacogenomics J
    Fernandez CA et al., 2015, Genome-wide analysis links NFATC2 with asparaginase hypersensitivity., Blood
    Pastorczak A et al., 2014, Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment., Leuk Res
    Peng et al., 2001, Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells., Br. J. Cancer
    Khater F et al., 2017, KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia., Blood
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.
    Hoogerbrugge et al., 1997, Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity., Leukemia
    Liu C et al., 2016, Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia., J Clin Oncol
    Chen SH et al., 2010, Genetic variations in GRIA1 on chromosome 5q33 related to asparaginase hypersensitivity., Clin Pharmacol Ther
    Fernandez CA et al., 2014, HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies., Blood
    Perez-Andreu V et al., 2013, Inherited GATA3 variants are associated with Ph-like childhood acute lymphoblastic leukemia and risk of relapse., Nat Genet
    Yang JJ et al., 2012, Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia., Blood
    Gutierrez-Camino A et al., 2017, PNPLA3 rs738409 and Hepatotoxicity in Children With B-cell Acute Lymphoblastic Leukemia: A Validation Study in a Spanish Cohort., Clin Pharmacol Ther
    Stams et al., 2005, Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia., Clin. Cancer Res.
  • ASPARAGINASE   ASNS

    Interaction Score: 24.73

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24268318 11556848 28069604


    Sources:
    NCI CIViC PharmGKB

  • ASPARAGINASE   CPA2

    Interaction Score: 8.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27114598


    Sources:
    PharmGKB

  • ASPARAGINASE   NFATC2

    Interaction Score: 8.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25987655


    Sources:
    PharmGKB

  • ASPARAGINASE   PYGL

    Interaction Score: 2.75

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007406


    Sources:
    PharmGKB

  • ASPARAGINASE   SOD2

    Interaction Score: 1.65

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27019981


    Sources:
    PharmGKB

  • ASPARAGINASE   PNPLA3

    Interaction Score: 1.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28744905


    Sources:
    PharmGKB

  • ASPARAGINASE   ETV6

    Interaction Score: 0.69

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15837750


    Sources:
    NCI

  • ASPARAGINASE   GATA3

    Interaction Score: 0.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24141364


    Sources:
    PharmGKB

  • ASPARAGINASE   NOTCH1

    Interaction Score: 0.48

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Ribociclib + Asparaginase
    Indication/Tumor Type T-cell adult acute lymphocytic leukemia
    Response Type decreased response

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • ASPARAGINASE   LPL

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9264396


    Sources:
    NCI

  • ASPARAGINASE   HLA-DRB1

    Interaction Score: 0.4

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25987655 24970932


    Sources:
    PharmGKB

  • ASPARAGINASE   RB1

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Evidence Type Actionable
    Approval Status Preclinical - Cell culture
    Response Type decreased response

    PMIDs:
    28151717


    Sources:
    JAX-CKB

  • ASPARAGINASE   GRIA1

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    20592726


    Sources:
    PharmGKB

  • ASPARAGINASE   TYMSOS

    Interaction Score: 0.32

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ASPARAGINASE   TYMS

    Interaction Score: 0.11

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • NCI: L-ASPARAGINASE

    • Version: 14-September-2017

    Alternate Names:
    C286 NCI drug code

    Drug Info:

    Publications:
    Peng et al., 2001, Hypermethylation of CpG islands in the mouse asparagine synthetase gene: relationship to asparaginase sensitivity in lymphoma cells. Partial methylation in normal cells., Br. J. Cancer
    Stams et al., 2005, Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia., Clin. Cancer Res.
    Hoogerbrugge et al., 1997, Transient hyperlipidemia during treatment of ALL with L-asparaginase is related to decreased lipoprotein lipase activity., Leukemia

  • PharmGKB: asparaginase

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Pastorczak A et al., 2014, Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment., Leuk Res
    Fernandez CA et al., 2014, HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies., Blood
    Fernandez CA et al., 2015, Genome-wide analysis links NFATC2 with asparaginase hypersensitivity., Blood

  • JAX-CKB: Asparaginase

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Pikman et al., 2017, Synergistic Drug Combinations with a CDK4/6 Inhibitor in T-cell Acute Lymphoblastic Leukemia., Clin. Cancer Res.

  • CIViC: ASPARAGINASE

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Khater F et al., 2017, KMT2E-ASNS: a novel relapse-specific fusion gene in early T-cell precursor acute lymphoblastic leukemia., Blood

  • ChemblDrugs: chembl:CHEMBL2108989

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21